Introduction
============

Breast cancer, which accounts for \~23% of all newly diagnosed cases of cancer and was responsible for 14% (458,400) of all mortalities due to cancer in 2008, is the leading cause of cancer-associated mortality among females ([@b1-ol-0-0-5180]). A previous study reported that the estrogen receptor (ER), which is expressed in \~75% of breast tumors, is considered the main target for the treatment of breast cancer, and women with breast tumors typically receive endocrine therapy ([@b2-ol-0-0-5180]).

Fulvestrant, which is a pure, steroidal antiestrogen, has been reported to completely suppress ERα activity by inactivating ERα-mediated genomic and non-genomic signaling; it is considered a promising drug for the treatment of breast cancer in postmenopausal women ([@b3-ol-0-0-5180]). However, ER-targeted therapies fail in ≤50% of patients with breast tumors due to the occurrence of *de novo* or acquired resistance ([@b2-ol-0-0-5180],[@b4-ol-0-0-5180]). It has been reported that microRNAs (miRNAs) have a pivotal role in breast cancer, and the overexpression of miRNA-221/222 has been suggested to be associated with the emergence of fulvestrant resistance in breast cancer ([@b5-ol-0-0-5180]).

In 2011, Rao *et al* ([@b6-ol-0-0-5180]) used a microarray expression profile to identify differentially expressed genes (DEGs) between antisense miRNA-221-transfected or miRNA-222-transfected MCF7-FR cells and negative control-transfected MCF7-FR cells, according to the cut-off criteria of P\<0.05 and \|log~2~ fold change (FC)\| \>1.2. It was demonstrated that activation of β-catenin by miRNA-221/222 led to estrogen-independent growth and fulvestrant resistance, as well as to repression of transforming growth factor-β-mediated growth inhibition ([@b6-ol-0-0-5180]). However, another study reported different mechanisms for the occurrence of fulvestrant resistance in breast cancer ([@b7-ol-0-0-5180]). Tangkeangsirisin and Serrero ([@b8-ol-0-0-5180]) demonstrated that progranulin induced human breast cancer resistance to fulvestrant by inhibiting the apoptosis of breast cancer cells. In addition, the broad-spectrum metalloproteinase inhibitor BB-94 has been demonstrated to inhibit the growth of fulvestrant-resistant breast cancer cell lines, as well as the activation of human epidermal growth factor receptor 3 and extracellular signal-regulated kinase in these cells ([@b9-ol-0-0-5180]). Therefore, it is important to further screen for biomarkers associated with fulvestrant-resistance in breast cancer.

Using the same microarray data as Rao *et al* ([@b6-ol-0-0-5180]), the present study aimed to further screen for DEGs in antisense miRNA-221-transfected and antisense miRNA-222-transfected MCF7-FR cells. The linear models for microarray data (limma) package, based on a wide threshold range (P\<0.05 and \|log~2~ FC\| \>1), was used to identify DEGs associated with fulvestrant-resistant breast cancer. In addition, a Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed, and the targets of miRNA-221/222 were predicted using miRanda and TargetScan. A previous study suggested that analyses based on different statistical tests may produce different outcomes ([@b10-ol-0-0-5180]). Therefore, the present study may obtain a number of results different from the data obtained in the initial study by Rao *et al* ([@b6-ol-0-0-5180]).

Materials and methods
=====================

### Microarray data

The GSE19777 transcription profile used by Rao *et al* ([@b6-ol-0-0-5180]) was downloaded from the Gene Expression Omnibus database (<http://www.ncbi.nlm.nih.gov/geo/>). The profile was based on the GPL570 dataset, which was obtained using the \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix, Inc., Santa Clara, CA, USA). In total, nine samples were included in the dataset, including three samples of antisense miRNA-221-transfected fulvestrant-resistant MCF7-FR breast cancer cells, three samples of antisense miRNA-222-transfected fulvestrant-resistant MCF7-FR cells and three samples of control inhibitor (green fluorescent protein)-treated fulvestrant-resistant MCF7-FR cells (negative control). In addition, the probe annotation information mapping the probes of genes was downloaded from Bioconductor (<http://www.bioconductor.org/>).

### Dataset preprocessing and DEG analysis

The R package from Affymetrix, Inc., was used to normalize the raw CEL data from the DNA microarrays ([@b11-ol-0-0-5180]). The downloaded expression profile was mapped to the corresponding gene symbols. Average expression values were used for the genes with multiple probes. Subsequently, the limma package in R/Bioconductor (<https://bioconductor.org/packages/release/bioc/html/limma.html>) was used to screen for DEGs in the antisense miRNA-221-transfected and miRNA-222-transfected MCF7-FR cells, as compared with the negative control. The cut-off criteria for the DEGs were P\<0.05 and \|log~2~ FC\| \>1. The top ten upregulated and downregulated genes in the antisense miRNA-221-transfected and antisense miRNA-222-transfected MCF7-FR cells are indicated in [Table I](#tI-ol-0-0-5180){ref-type="table"}. Next, the pheatmap package (<https://cran.r-project.org/web/packages/pheatmap/index.html>) in R was used to perform two-way clustering ([@b12-ol-0-0-5180]), based on the Euclidean distance ([@b13-ol-0-0-5180]).

### Gene set enrichment analysis (GSEA)

GSEA, which is a computational method that determines whether an *a priori* defined set of genes exhibits statistically significant and concordant differences between two biological states ([@b14-ol-0-0-5180]), was used to conduct the pathway enrichment analysis based on the expression levels of DEGs in the antisense miRNA-221-transfected and miRNA-222-transfected MCF7-FR cells. A gene count between 15 and 500 and P\<0.01 were set as the criteria to filter the pre-defined gene sets. In addition, the distant regulatory elements of co-regulated genes tool (<http://dire.dcode.org>), which enables the prediction of distant regulatory elements in higher eukaryotic genomes ([@b15-ol-0-0-5180]), was applied to screen for transcription factors associated with the DEGs in the enriched pathways.

### miRNA-messenger (m) RNA regulatory network construction

Prediction of the targets of miRNA-221 and miRNA-222 was performed using the miRanda algorithm (<http://microrna.sanger.ac.uk/targets/v5/>) and TargetScan 4.2 (<http://www.targetscan.org/>). Subsequently, the miRNA-mRNA regulatory network, depicting interactions between the miRNAs and target DEGs (upregulated DEGs only) was constructed and visualized using Cytoscape ([@b16-ol-0-0-5180]).

Results
=======

### Preprocessing and DEG analysis

The box plots of the expression values for all genes in every sample following normalization are represented in [Fig. 1A and B](#f1-ol-0-0-5180){ref-type="fig"}. In total, 492 DEGs, including 247 upregulated \[such as phosphoribosyl pyrophosphate synthetase 1-like 1 (*PRPS1L1*) and secreted frizzled-related protein 5 (*SFRP5*)\] and 245 downregulated (such as LIM homeobox 8 and proteasome subunit beta 8) DEGs, were identified in the antisense miRNA-221-transfected MCF7-FR cells compared with the negative control, while 404 DEGs, including 255 upregulated \[such as *PRPS1L1* and claudin 8 (*CLDN8*)\] and 149 downregulated (such as parathyroid hormone and Prader Willi/Angelman region RNA 5) DEGs, were identified in the antisense miRNA-222-transfected MCF7-FR cells compared with the negative control. The two-way hierarchical cluster analyses of the DEGs in the miRNA-221- and miRNA-222-transfected cells are represented in [Fig. 1C and D](#f1-ol-0-0-5180){ref-type="fig"}.

### GSEA

Three pathways were significantly enriched in the antisense miRNA-221-transfected MCF7-FR cells compared with the negative control, while ten pathways were significantly enriched in the miRNA-221-transfected MCF7-FR cells compared with the negative control ([Table II](#tII-ol-0-0-5180){ref-type="table"}). In addition, two pathways, including the pentose phosphate pathway (PPP) and olfactory transduction, were enriched in both the antisense miRNA-221-transfected and miRNA-222-transfected MCF7-FR cells, as compared with the negative control ([Table II](#tII-ol-0-0-5180){ref-type="table"}). Notably, the DEGs *SFRP5* and *CLDN8* were significantly enriched in the Wnt signaling pathway and the cell adhesion molecules (CAMs) pathway, respectively ([Table II](#tII-ol-0-0-5180){ref-type="table"}).

Screening for transcription factors associated with the genes in the enriched pathways identified 123 transcription factors associated with the genes in the CAMs pathway. Furthermore, 94 transcription factors were associated with the genes enriched in the Wnt signaling pathway, and 87 transcription factors were associated with the genes enriched in the PPP ([Table III](#tIII-ol-0-0-5180){ref-type="table"}).

### Regulatory network analysis

According to the TargetScan and miRanda databases, 530 genes were targets of miRNA-221 and 488 genes were targets of miRNA-221. Of the 530 target genes of miRNA-221, six were DEGs, including four upregulated genes \[recombination activating gene 1, leucine-rich repeats and calponin homology domain containing 2, methionine sulfoxide reductase B3 (*MSRB3*) and neurexophilin 1 (*NXPH1*)\], in the antisense miRNA-221-transfected MCF7-FR cells. Of the 488 target genes of miRNA-222, ten were DEGs, including eight upregulated genes (*MSRB3*, *NXPH1*, protocadherin (*PCDH*) *A2*, *PCDH10*, chromosome 9 open reading frame 135, prostaglandin E receptor 2, MAGE-like-2 and family with sequence similarity 160 member B1), in the antisense miRNA-222-transfected MCF7-FR cells. The miRNA-target regulatory network is represented in [Fig. 2](#f2-ol-0-0-5180){ref-type="fig"}.

Discussion
==========

In the present study, 492 and 404 DEGs were identified in the antisense miRNA-221-transfected MCF7-FR cells and the antisense miRNA-222-transfected MCF7-FR cells, respectively, as compared with the negative control. GSEA revealed that the PPP was significantly enriched in the antisense miRNA-221-transfected and antisense miRNA-222-transfected MCF7-FR cells. Furthermore, 87 transcription factors were identified for the genes enriched in the PPP, which suggested that the PPP was significantly regulated in these cells. The PPP produces two substrates, ribose 5-phosphate and nicotinamide adenine dinucleotide phosphate, which are necessary for the division of cells and serve as buffers to prevent reactive oxygen species-induced cell death and apoptosis ([@b17-ol-0-0-5180]). Alterations in the PPP activity have been reported to occur during cancer development and progression ([@b18-ol-0-0-5180]). In addition, an increase in the levels of various PPP metabolites in the breast epithelia, including sedoheptulose 7-phosphate and hexose phosphate intermediates, has been reported to occur during the transition from normal breast epithelial cells to transformed cells, as well as during the transition from non-metastatic to metastatic tumors ([@b19-ol-0-0-5180],[@b20-ol-0-0-5180]).

In the present study, the Wnt signaling pathway was significantly enriched in the antisense miRNA-222-transfected MCF7-FR cells compared with the normal control-transfected cells. A total of 94 transcription factors were associated with the genes enriched in the Wnt signaling pathway, which suggested that this pathway was highly regulated in the miRNA-222-transfected MCF7-FR cells. A previous study reported that the activation of the Wnt signaling pathway could lead to the metastasis of breast cancer ([@b21-ol-0-0-5180]). In addition, the blockage of Wnt signaling has been demonstrated to inhibit cell proliferation and migration, and to induce apoptosis in triple-negative breast cancer cells ([@b22-ol-0-0-5180]).

In the present study, the CAMs pathway was significantly enriched in the antisense miRNA-222-transfected MCF7-FR cells compared with the normal control-transfected cells. A total of 123 transcription factors were associated with the genes enriched in this pathway. CAMs are membrane receptors that mediate cell-cell and cell-matrix interactions, and have an essential role in transducing intracellular signals responsible for adhesion, migration, invasion, angiogenesis and organ-specific metastasis ([@b23-ol-0-0-5180]). Adhesion molecules, including E-cadherin and carcinoembryonic antigen, have been associated with the process of metastasis in breast cancer cells ([@b24-ol-0-0-5180]). Taken together, these results suggested that the PPP, Wnt signaling pathway and CAMs pathway may be associated with the resistance of breast cancer to fulvestrant.

In the miRNA-target regulatory network, miR-222 was observed to target *PCDH10*. *PCDH10* is a member of the mammalian cadherin superfamily, which has key roles in cell migration and calcium-dependent, cadherin-mediated homophilic cell-cell interactions ([@b25-ol-0-0-5180]). A previous study identified *PCDH10* as a candidate tumor suppressor in nasopharyngeal, esophageal and various other carcinomas, in which it was associated with frequent methylation ([@b26-ol-0-0-5180]). As a result, *PCDH10* targeted by miR-222 could be associated with the resistance of breast cancer to fulvestrant.

In conclusion, the results of the present study suggested that the PPP, Wnt signaling pathway and CAMs KEGG pathway, as well as *PCDH10*, may be associated with the development of fulvestrant resistance in patients with breast cancer. However, further studies are required to elucidate the underlying mechanisms.
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###### 

Top ten upregulated and downregulated DEGs in the antisense miRNA-221-transfected and antisense miRNA-222-transfected MCF7-FR cells, as compared with negative control-transfected MCF7-FR cells.

                  Antisense miRNA-221 vs. control   Antisense miRNA-222 vs. control                                          
  --------------- --------------------------------- --------------------------------- ---------- ---------------- ---------- ----------
  Downregulated   *LHX8*                            −4.17614                          0.000175   *PTH*            −3.49280   0.000184
                  *PSMB8*                           −4.06074                          0.000204   *PWAR5*          −3.27792   0.009442
                  *FLG2*                            −3.99026                          0.001523   *IYD*            −3.20234   0.001261
                  *TRPC5*                           −3.83132                          0.002291   *ICAM5*          −2.87824   0.017322
                  *OLFM4*                           −3.51933                          0.000522   *DAOA-AS1*       −2.83576   0.044589
                  *KERA*                            −3.37161                          0.006165   *STARD13-AS*     −2.79578   0.005935
                  *GIMAP2*                          −3.19819                          0.008755   *WDR86-AS1*      −2.75129   0.021120
                  *CYP4F30P*                        −2.92305                          0.042475   *IZUMO2*         −2.68134   0.028787
                  *LOC100505635*                    −2.89457                          0.041871   *RAG2*           −2.67795   0.006909
                  *SLC15A3*                         −2.88269                          0.000007   *C1orf192*       −2.66616   0.022020
  Upregulated     *PRPS1L1*                         3.81365                           0.002733   *OR2L13*         3.55457    0.007431
                  *ARHGAP36*                        3.33814                           0.000913   *PRPS1L1*        3.54601    0.002105
                  *CXorf58*                         3.28644                           0.000074   *SH3RF3-AS1*     3.34868    0.000066
                  *LINC00567*                       3.24582                           0.000653   *CXorf58*        3.15695    0.028128
                  *DYDC1*                           3.18358                           0.026382   *LOC100505676*   3.11364    0.001263
                  *OR2L13*                          2.88576                           0.003734   *LINC00950*      2.92266    0.001549
                  *MLIP*                            2.83880                           0.036347   *NXPH1*          2.90566    0.000380
                  *KLKB1*                           2.79668                           0.015902   *MSTN*           2.89563    0.000007
                  *LINC00950*                       2.75805                           0.001693   *DZIP1*          2.86233    0.007720
                  *OR10A5*                          2.74849                           0.011940   *CPEB2-AS1*      2.85775    0.015210

FC, fold change; adj.P.Val, adjusted P-value; miRNA, microRNA; DEGs, differentially expressed genes.

###### 

Enriched pathways for DEGs in the miRNA-221-transfected and miRNA-222-transfected MCF7-FR cells, as compared with the negative control-transfected MCF7-FR cells.

  Groups                                          Pathway                                           Counts   P-value   Top 10 DEGs
  ----------------------------------------------- ------------------------------------------------- -------- --------- ---------------------------------------------------------------------------------------
  Antisense miRNA-221-transfected MCF7-FR cells   PPP                                                 26     0         *RPE, RPIA, PGM2, PGLS, PRPS2, FBP2, PFKM, PFKL, TALDO1, TKT*
                                                  Histidine metabolism                                27     0         *CNDP1, MAOB, MAOA, ALDH1B1, ALDH2, METTL6, WBSCR22, HAL, HNMT*
                                                  Olfactory transduction                            114      0         *CALM2, CALM1, OR11H4, OR52W1, OR5AU1, ADRBK2, OR2M2, OR2M7, OR2T33, OR4F5*
  Antisense miRNA-222-transfected MCF7-FR cells   PPP                                                 26     0         *RPE, RPIA, PGM2, PGLS, PRPS2, FBP2, PFKM, PFKL, TALDO1, TKT*
                                                  Taste transduction                                  44     0         *TAS2R60, GRM4, PLCB2, ADCY8, ADCY6, TAS2R42, TAS1R2, TAS1R1, TRPM5 ACCN1*
                                                  Propanoate metabolism                               31     0         *ACSS2 ALDH1B1, ABAT, LOC283398, ALDH2, ACADM, ACAT2, ACAT1, LDHC, MCEE*
                                                  Wnt signaling pathway                             144      0         *JUN, LRP5, LRP6, PPP3R2, SFRP2, SFRP1, PPP3CC, VANGL1, PPP3R1, FZD1*
                                                  Arrhythmogenic right ventricular cardiomyopathy     73     0         *CACNA2D1, CACNB1, LOC100418883, CACNB2, CACNB3, CACNB4, CACNG1, ITGA9, CACNG8, RYR2*
                                                  Axon guidance                                     127      0         *UNC5B, PLXNB2, PPP3R2, PPP3CC, PPP3R1, PAK4, NGEF, SEMA4C, SEMA4A, PLXNC1*
                                                  Prion diseases                                      35     0         *NCAM2, EGR1, NCAM1, ELK1, NOTCH1, PRKX, C6, CCL5, C5, IL1B*
                                                  Cell adhesion molecules                           125      0         *CDH5, JAM3, CDH3, NLGN3, CDH4, CD80, NLGN1, CD86, CD28, CD274*
                                                  Neuroactive ligand receptor interaction           252      0         *PTGFR, PTGER2, PTGER1, PTGER4, PTGER3, CALCRL, TACR3, PTGIR, ADRB3, ADRB2*
                                                  Olfactory transduction                            114      0         *CALM2, CALM1, OR11H4, OR52W1, OR5AU1, ADRBK2, OR2M2, OR2M7, OR2T33, OR4F5*

DEGs, differentially expressed genes; miRNA, microRNA; PPP, pentose phosphate pathway.

###### 

Counts of transcription factors for the differentially expressed genes in the enriched pathways.

  Group                                           KEGG pathway                                      Counts
  ----------------------------------------------- ------------------------------------------------- --------
  Antisense miRNA-221-transfected MCF7-FR cells   PPP                                                 87
                                                  Histidine metabolism                                80
                                                  Olfactory transduction                              95
  Antisense miRNA-222-transfected MCF7-FR cells   PPP                                                 87
                                                  Taste transduction                                  76
                                                  Propanoate metabolism                               76
                                                  Wnt signaling pathway                               94
                                                  Arrhythmogenic right ventricular cardiomyopathy   116
                                                  Axon guidance                                     104
                                                  Prion diseases                                      79
                                                  Cell adhesion molecules                           123
                                                  Neuroactive ligand receptor interaction           113
                                                  Olfactory transduction                              95

KEGG, Kyoto Encyclopedia of Genes and Genomes; miRNA, microRNA; PPP, pentose phosphate pathway.
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